WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2013163229) DR5 LIGAND DRUG CONJUGATES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2013/163229 International Application No.: PCT/US2013/037861
Publication Date: 31.10.2013 International Filing Date: 23.04.2013
IPC:
A61K 39/395 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants: SEATTLE GENETICS, INC.[US/US]; 21823 - 30th Dr. S.E. Bothell, Washington 98021, US
DAIICHI SANKYO CO., LTD.[JP/JP]; 3-5-1, Nihonbashi-honcho, Chuo-ku Tokyo, Tokyo 103-8426, JP
Inventors: OHTSUKA, Toshiaki; JP
ICHIKAWA, Kimihisa; JP
YADA, Ayumi; JP
Agent: FLANAGAN, Lisa Dornbach; Kilpatrick Townsend & Stockton LLP Eighth Floor Two Embarcadero Center San Francisco, California 94111, US
Priority Data:
61/637,80824.04.2012US
Title (EN) DR5 LIGAND DRUG CONJUGATES
(FR) CONJUGUÉS LIGAND-MÉDICAMENT DR5
Abstract:
(EN) Ligand Drug Conjugates are provided having a DRS binding moiety attached via linking groups and/or spacers to a therapeutic agent that are effective in treatment of various cancers. In some embodiments, the Ligand Drug Conjugate has the formula: L-(LU-D)p, where L is a Ligand unit, LU is a Linker unit and D is a Drug unit (or cytotoxic agent). The subscript p is an integer of from 1 to 20. Accordingly, the Ligand Drug Conjugates comprise a Ligand unit covalently linked to at least one Drug unit. The Drug units can be covalently linked directly or via a Linker unit (-LU-). The Ligand unit is a DR5 binding agent, such as an anti-DRS antibody.
(FR) La présente invention concerne des conjugués ligand-médicament possédant un fragment de liaison DR5 fixé par le biais de groupes de liaison et/ou d'espaceurs à un agent thérapeutique, qui sont efficaces dans le traitement de divers cancers.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)